arrow
M

Marliese Alexander

peter maccallum cancer center
H指数:21
被引数:1,437

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)

ROS1重排非小细胞肺癌在演变的治疗时代中的真实世界治疗序列与生存情况:AURORA多中心登记研究(AURORA-ROS1)的结果

2026-06-170
PRE
A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer

一项随机对照试验:评估睡眠、癌症与休息(SleepCaRe)试验以提高接受化疗的乳腺癌女性患者的生活质量

2026-03-220
OAAI
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial

基于生物标志物指导的抗血栓预防在癌症患者中的长期生存结局:TARGET-TP随机试验的扩展随访研究

2026-03-070
OA
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis

PD-L1对EGFR突变型NSCLC一线奥希替尼疗效的影响:AURORA25研究真实世界数据与荟萃分析

2025-11-240
PRE
Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia

与澳大利亚接受氟嘧啶类抗肿瘤治疗患者的标准治疗方案相比,DPYD基因分型的成本效益分析。

2025-10-270
OA
EP.17.02 Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry

EP.17.02 维多利亚肺癌登记系统中的原住民澳大利亚人治疗与生存结局

2025-10-230
PRE
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers
2025-03-010
OAAI
Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study

完成率:接受同期化放疗治疗III期非小细胞肺癌患者的完成率及其在巩固免疫治疗时代的意义:一项队列研究

2025-02-210
PRE
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial
2024-11-290
PRE
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
2024-02-074
OAAI